| scholarly article | Q13442814 |
| P356 | DOI | 10.1586/1744666X.2.6.915 |
| P698 | PubMed publication ID | 20476979 |
| P50 | author | Luigi E. Adinolfi | Q89603631 |
| Rosa Zampino | Q59158585 | ||
| Aldo Marrone | Q64342034 | ||
| P2093 | author name string | Giuseppe Ruggiero | |
| P2860 | cites work | Hepatitis B Virus e Antigen Variants | Q24810141 |
| Natural history and treatment of hepatitis B virus and hepatitis C virus coinfection | Q24815355 | ||
| Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B | Q28212394 | ||
| A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B | Q28266038 | ||
| Acute liver graft failure due to emergence of lamivudine resistant hepatitis B virus: rapid resolution during treatment with adefovir | Q28364197 | ||
| Hepatitis B virus biology | Q33855246 | ||
| Management of hepatitis B: 2000--summary of a workshop | Q34263265 | ||
| Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures | Q34302587 | ||
| Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. | Q34500537 | ||
| Lamivudine for patients with chronic hepatitis B and advanced liver disease | Q34551713 | ||
| Randomized, double-blind study of emtricitabine (FTC) plus clevudine versus FTC alone in treatment of chronic hepatitis B. | Q34648598 | ||
| Pharmacokinetics of telbivudine in subjects with various degrees of hepatic impairment | Q34648651 | ||
| Management of chronic viral hepatitis before and after renal transplantation | Q34917901 | ||
| Management of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. | Q35020833 | ||
| Management of chronic hepatitis B. | Q35068048 | ||
| Hepatitis B virus: old, new and future approaches to antiviral treatment | Q35091302 | ||
| Pediatric issues in new therapies for hepatitis B and C | Q35122558 | ||
| Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial | Q35359761 | ||
| Long term effect of alpha interferon in children with chronic hepatitis B. | Q35360056 | ||
| Management of hepatitis B in liver transplantation patients | Q35802364 | ||
| Entecavir for the treatment of chronic hepatitis B. | Q35964745 | ||
| Treatment of hepatitis B and C after liver transplantation. Part 1, hepatitis B. | Q36028324 | ||
| Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance. | Q36177722 | ||
| Therapeutic implications of hepatitis B virus genotypes. | Q36338675 | ||
| Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study. | Q39130516 | ||
| Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro | Q40164099 | ||
| Antisense oligonucleotides targeted against asialoglycoprotein receptor 1 block human hepatitis B virus replication | Q40316858 | ||
| Efficient inhibition of hepatitis B virus replication by hammerhead ribozymes delivered by hepatitis delta virus | Q40391390 | ||
| Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir | Q40887887 | ||
| Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. | Q41277179 | ||
| Safety and efficacy of alamifovir in patients with chronic hepatitis B virus infection | Q42172163 | ||
| Core promoter mutations 3 years after anti-hepatitis B e seroconversion in patients with chronic hepatitis B or hepatitis B and C infection and cancer remission | Q43040340 | ||
| Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens | Q43541564 | ||
| Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. | Q43662700 | ||
| Vertical transmission of hepatitis B virus despite maternal lamivudine therapy | Q43978530 | ||
| Sequential analysis of hepatitis B virus core promoter and precore regions in cancer survivor patients with chronic hepatitis B before, during and after interferon treatment | Q43993339 | ||
| Clinical trial of lamivudine in children with chronic hepatitis B. | Q44010592 | ||
| Risk of hepatitis B transmission in breast-fed infants of chronic hepatitis B carriers | Q44019721 | ||
| Combination therapy for children with chronic hepatitis B virus infection | Q44118743 | ||
| Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. | Q44226653 | ||
| Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. | Q44329201 | ||
| Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. | Q44355905 | ||
| Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection | Q44489299 | ||
| CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans | Q44523432 | ||
| Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase | Q44532948 | ||
| A severe hepatitis flare in an HBV-HCV coinfected patient during combination therapy with ?-interferon and ribavirin | Q44593332 | ||
| Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B. | Q44652637 | ||
| Reconstitution of hepatitis B virus (HBV)-specific T cell responses with treatment of human immunodeficiency virus/HBV coinfection | Q44692010 | ||
| Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus | Q44709441 | ||
| Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. | Q44709445 | ||
| Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. | Q44929883 | ||
| Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. | Q45061899 | ||
| Interferon/long-term lamivudine combination therapy in anti-HBe positive chronic hepatitis B patients | Q45074262 | ||
| Combined interferon plus lamivudine treatment in young patients with dual HBV (HBeAg positive) and HCV chronic infection | Q45175727 | ||
| A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone | Q45265105 | ||
| Three-phase sequential combined treatment with lamivudine and interferon in young patients with chronic hepatitis B. | Q45273542 | ||
| Variant of hepatitis B virus with primary resistance to adefovir | Q45417270 | ||
| Clinical reactivation during lamivudine treatment correlates with mutations in the precore/core promoter and polymerase regions of hepatitis B virus in patients with anti-hepatitis B e-positive chronic hepatitis. | Q45423590 | ||
| Posttreatment exacerbation of hepatitis B virus (HBV) infection in long-term HBV trials of emtricitabine | Q45428858 | ||
| Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine | Q45739411 | ||
| Therapeutic vaccination of woodchucks against chronic woodchuck hepatitis virus infection. | Q45759560 | ||
| Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. | Q46575197 | ||
| Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. | Q46575199 | ||
| Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation | Q46707913 | ||
| A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients | Q46757241 | ||
| Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. | Q46794204 | ||
| Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients | Q46798240 | ||
| Heart transplantation in patients with chronic hepatitis B: clinical evolution, molecular analysis, and effect of treatment | Q46825340 | ||
| A partially overlapping treatment course with lamivudine and interferon in hepatitis B e antigen-negative chronic hepatitis B. | Q46879602 | ||
| A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. | Q46981468 | ||
| Protective and therapeutic effect of DNA-based immunization against hepadnavirus large envelope protein. | Q51473519 | ||
| Enhancement of natural killer activity and interferon induction by different acyclic nucleoside phosphonates. | Q54223299 | ||
| Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B | Q57487519 | ||
| P433 | issue | 6 | |
| P921 | main subject | chronic hepatitis B | Q55779876 |
| P304 | page(s) | 915-929 | |
| P577 | publication date | 2006-11-01 | |
| P1433 | published in | Expert Review of Clinical Immunology | Q15733763 |
| P1476 | title | Treatment of chronic hepatitis B: efficacy of current drugs and prospects for the future | |
| P478 | volume | 2 |
Search more.